---
type: paper
citekey: "chen2026harmonizationand"
title: "Harmonization and integration of pharmacogenomics screens."
year: 2026
journal: "Bioinformatics"
status: bioflow-analyzed
major_topic: "Computational drug discovery"
subtopics:
  - "Pharmacogenomics screen integration"
doi: "10.1093/bioinformatics/btag382"
pmid: "42286248"
url: "https://doi.org/10.1093/bioinformatics/btag382"
abstract_summary: "MOTIVATION: Large pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs. Although centralized repositories have consolidated data access, the diversity of experimental platforms and response metrics used in these screens have made it challenging to integrate and compare their measured drug responses. Towards better pharmacogenomic data harmonization, we surveyed a range of data analysis protocols based on different curve-fitting functions (sigmoid, piecewise linear), different response metrics (IC50, EC50, integrated AUC), and different drug concentration windows (full range or truncated). RESULTS: We found that an AUC derived from a sigmoidal curve fitted to a truncated dose range yields the strongest agreement between screening platforms, significantly bettering other protocols surveyed. This harmonization procedure also best aligns drug responses across successive iterations of the same platform. These findings broadly inform efforts to integrate drug response data in large-scale analyses. AVAILABILITY: The source code to generate drug response profiles and correlations are available at https://github.com/digitaltumors/Pharmacogenomics_Screens_Harmonization.git."
prior_limitations:
  - "기존 Pharmacogenomics screen integration 연구는 대규모 데이터, 재현 가능한 benchmark, 또는 임상/생물학적 해석 연결이 충분하지 않았다."
solution: "Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다."
differentiator: "Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다."
healthcare_relevance: "질병 위험 예측, 진단 보조, 환자 stratification, 또는 임상 유전체 해석으로 확장될 수 있다."
datasets:
  - "pharmacogenomics screens"
methods:
  - "Abstract-level computational or genomic analysis"
topics:
  - "Computational drug discovery"
  - "Pharmacogenomics screen integration"
tags:
  - paper
  - graph-topic
  - major-computational-drug-discovery
  - subtopic-pharmacogenomics-screen-integration
---
# Harmonization and integration of pharmacogenomics screens.
## Healthcare relevance
질병 위험 예측, 진단 보조, 환자 stratification, 또는 임상 유전체 해석으로 확장될 수 있다.
## Analysis
- Abstract: MOTIVATION: Large pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs. Although centralized repositories have consolidated data access, the diversity of experimental platforms and response metrics used in these screens have made it challenging to integrate and compare their measured drug responses. Towards better pharmacogenomic data harmonization, we surveyed a range of data analysis protocols based on different curve-fitting functions (sigmoid, piecewise linear), different response metrics (IC50, EC50, integrated AUC), and different drug concentration windows (full range or truncated). RESULTS: We found that an AUC derived from a sigmoidal curve fitted to a truncated dose range yields the strongest agreement between screening platforms, significantly bettering other protocols surveyed. This harmonization procedure also best aligns drug responses across successive iterations of the same platform. These findings broadly inform efforts to integrate drug response data in large-scale analyses. AVAILABILITY: The source code to generate drug response profiles and correlations are available at https://github.com/digitaltumors/Pharmacogenomics_Screens_Harmonization.git.
- Prior limitation: 기존 Pharmacogenomics screen integration 연구는 대규모 데이터, 재현 가능한 benchmark, 또는 임상/생물학적 해석 연결이 충분하지 않았다.
- Differentiator: Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
## BioProject-style analysis
### Evidence level
- Source level: Screening report generated from journal/PubMed metadata, PubMed record (https://pubmed.ncbi.nlm.nih.gov/42286248/), DOI landing page (https://doi.org/10.1093/bioinformatics/btag382).
- Missing source material: Full PDF, figure panels, supplementary tables, exact benchmark settings, and author-stated limitations beyond abstract metadata were not extracted in this import.
### Background
- Problem context: MOTIVATION: Large pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs.
- Why the problem matters: 질병 위험 예측, 진단 보조, 환자 stratification, 또는 임상 유전체 해석으로 확장될 수 있다.
- Prior work baseline: 기존 Pharmacogenomics screen integration 연구는 대규모 데이터, 재현 가능한 benchmark, 또는 임상/생물학적 해석 연결이 충분하지 않았다.
- Gap that remains: full text 확인 필요. 현재 note는 abstract-level screening 기반이다.
### Overview
- Core question: 이 논문은 Computational drug discovery -> Pharmacogenomics screen integration 흐름에서 어떤 새 데이터, 방법, 또는 해석을 제공하는가?
- Paper's framing: MOTIVATION: Large pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs. Although centralized repositories have consolidated data access, the diversity of experimental platforms and response metrics used in these screens have made it challenging to integrate and compare their measured drug responses. Towards better pharmacogenomic data harmonization, we surveyed a range of data analysis protocols based on different curve-fitting functions (sigmoid, piecewise linear), different response metrics (IC50, EC50, integrated AUC), and different drug concentration windows (full range or truncated). RESULTS: We found that an AUC derived from a sigmoidal curve fitted to a truncated dose range yields the strongest agreement between screening platforms, significantly bettering other protocols surveyed. This harmonization procedure also best aligns drug responses across successive iterations of the same platform. These findings broadly inform efforts to integrate drug response data in large-scale analyses. AVAILABILITY: The source code to generate drug response profiles and correlations are available at https://github.com/digitaltumors/Pharmacogenomics_Screens_Harmonization.git.
- Input / cohort / material: pharmacogenomics screens
- Output / endpoint: Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
- Expected clinical or biological impact: 질병 위험 예측, 진단 보조, 환자 stratification, 또는 임상 유전체 해석으로 확장될 수 있다.
### Methods
- Method type: Abstract-level computational or genomic analysis
- Key input: pharmacogenomics screens
- Core processing step: abstract metadata만으로 작성했으므로 세부 protocol, parameter, model architecture, validation split은 full text 확인 필요.
- Comparator / baseline: 기존 Pharmacogenomics screen integration 연구는 대규모 데이터, 재현 가능한 benchmark, 또는 임상/생물학적 해석 연결이 충분하지 않았다.
- Output: Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
- Why this differs from prior methods: Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
### Figures / Tables
- PDF/figure 확인 필요. 현재 local note에는 figure panel, caption, table, supplementary evidence가 포함되지 않았다.
### Results
#### Dataset / cohort results
- Dataset or cohort: pharmacogenomics screens
- Purpose: Pharmacogenomics screen integration branch에서 핵심 contribution을 평가한다.
- Scale: abstract에서 확인 가능한 범위만 기록했다.
- Baseline / comparator: 기존 Pharmacogenomics screen integration 연구는 대규모 데이터, 재현 가능한 benchmark, 또는 임상/생물학적 해석 연결이 충분하지 않았다.
- Metric / endpoint: full text 확인 필요; 현재 endpoint는 Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
- Main result: MOTIVATION: Large pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs. Although centralized repositories have consolidated data access, the diversity of experimental platforms and response metrics used in these screens have made it challenging to integrate and compare their measured drug responses. Towards better pharmacogenomic data harmonization, we surveyed a range of data analysis protocols based on different curve-fitting functions (sigmoid, piecewise linear), different response metrics (IC50, EC50, integrated AUC), and different drug concentration windows (full range or truncated). RESULTS: We found that an AUC derived from a sigmoidal curve fitted to a truncated dose range yields the strongest agreement between screening platforms, significantly bettering other protocols surveyed. This harmonization procedure also best aligns drug responses across successive iterations of the same platform. These findings broadly inform efforts to integrate drug response data in large-scale analyses. AVAILABILITY: The source code to generate drug response profiles and correlations are available at https://github.com/digitaltumors/Pharmacogenomics_Screens_Harmonization.git.
- How this supports the paper's claim: abstract 또는 metadata가 제시한 핵심 claim을 taxonomy placement와 연결했다.
#### Overall result pattern
- Repeated pattern: Computational drug discovery 분야에서 최신 2025-2026 trend를 반영하는 branch로 분류된다.
- Strongest result: Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
- Result caveat: abstract-level import라서 수치, figure, external validation은 추가 검토가 필요하다.
### Limitations
- Author-stated limitations: full text 확인 필요.
- Analyst-judged limitations: 현재 근거는 screening report와 abstract metadata에 제한된다.
- Missing validation: 독립 cohort, cross-platform replication, prospective utility, benchmark table은 paper-specific full text review가 필요하다.
- Weak link between evidence and claim: claim은 기록했지만 figure-level evidence extraction은 아직 수행하지 않았다.
### Final Takeaways
- Main takeaway: Harmonization and integration of pharmacogenomics screens. 논문은 Pharmacogenomics screen integration 문제를 Computational drug discovery 맥락에서 다루는 새 데이터, 방법, 또는 해석 프레임을 제공한다.
- Why this matters for healthcare or biology: 질병 위험 예측, 진단 보조, 환자 stratification, 또는 임상 유전체 해석으로 확장될 수 있다.
- Next-paper idea: full text/PDF를 회수해 cohort, baseline, metric, figure, author-stated limitation을 deeper review note로 보강한다.
- Reusable idea for this vault: Computational drug discovery -> Pharmacogenomics screen integration branch에서 관련 paper들과 trend 비교에 사용한다.
## Source
- Journal: Bioinformatics
- DOI: https://doi.org/10.1093/bioinformatics/btag382
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42286248/
- Article: https://doi.org/10.1093/bioinformatics/btag382
- Journal source: https://academic.oup.com/bioinformatics
- Secondary journal source: https://academic.oup.com/bioinformatics/advance-articles
- Screening report: reports/bioinformatics/2026-07-07_11-13-00.md
